한국융합학회논문지 (Journal of the Korea Convergence Society)

  • 제13권1호
  • /
  • Pages.119-129
  • /
  • 2022
  • /
  • 2233-4890(pISSN)
  • /
  • 2713-6353(eISSN)
한국융합학회 (Korea Convergence Society)
권호 표지
DOI QR코드

DOI QR Code

수원시 소재 일개 종합병원 산부인과에서 자궁경부 질환 검사의 실태조사 : HPV와 세포학적 검사의 융합연구

Convergence research on cytological diagnosis of gynecological diseases and genital HPV : Based on data from the Obstetrics and Gynecology Department of a general hospital located in Suwon-si

  • 정유현 (단국대학교 의학대학원 의학레이저 협동과정) ;
  • 이준민 (단국대학교 보건과학대 임상병리학과) ;
  • 김종완 (단국대학교 의과대학 의학과) ;
  • 김재경 (단국대학교 보건과학대 임상병리학과)
  • Joung, You Hyun (Department of Medical Laser, Graduate School of Medicine, Dankook University) ;
  • Lee, Jun Min (Department of Biomedical Laboratory Science, College of Health Sciences, Dankook University) ;
  • Kim, Jong-Wan (Department of Laboratory Medicine, College of Medicine, Dankook University) ;
  • Kim, Jae Kyung (Department of Biomedical Laboratory Science, College of Health Sciences, Dankook University)
  • 투고 : 2021.10.19
  • 심사 : 2022.01.20
  • 발행 : 2022.01.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

자궁경부세포검사는 자궁경부암 선별검사로 널리 사용되어 왔다. 그러나, 위음성 비율이 높아 인유두종바이러스 중합효소연쇄반응 (HPV PCR) 검사로 보완이 제안되고 있다. HPV PCR 검사의 임상적 유용성을 확인하여, 자궁경부암을 예방하는 선별검사의 효과를 알아보고자 한다. 217명의 환자의 데이터를 분석하였고, 높은 HPV 감염률(46.1%)과 분산분석결과 연령 집단간 HPV 감염률에 유의한 차이가 보였다(P=0.015). 특히, 연구기간 중 CIN3 3건 상피세포암 1건이 관찰되었는데, 고위험군 HPV(16, 33)감염이 모두 관찰되었고, 20대와 30대 상피세포 이형성증 진단 환자에서 높은 고위험군 HPV감염이 관찰되었다. 따라서 이 연령대에 대한 광범위한 연구 및 예방 활동이 필요하며, 자궁암 예방을 위한 선별검사로써 세포학적 검사와 함께 HPV PCR 검사가 유용할 것으로 판단된다.

Cervical cytology has been widely used as a screening tool for cervical cancer. However, Human papillomavirus (HPV) detection and subtype testing are suggested to overcome the high false-negative rate associated with cytology. We aimed to investigate the clinical usefulness and infection rate in the HPV polymerase chain reaction (PCR) test performed in hospitals. HPV PCR data from 217 patients were analyzed. Analysis of variance revealed a significant difference in the infection rate among different age groups (P=0.015). The biopsy results showed that epithelial cell abnormalities and high HPV-positivity rate was observed in 1 (100%) subject aged <29 years, in 4 out of 5 (80%) patients in their 30s, and in 3 out of 4 (75%) patients aged ≥70 years. The prevalence of HPV infection was very high (46.1%). The highest prevalence (87.5%) was observed among patients in their <29, followed by those in their 30s (67.7%) and those in their 40s (31.9%).A high rate of epithelial cell abnormalities (≥ cervical intraepithelial neoplasia type 1, mild dysplasia) was observed in HPV-infected women aged<30 years. Therefore, extensive research and prevention activities are needed in this age group. HPV PCR testing is recommended to complement cervical cytology

키워드

참고문헌

  1. H. Sung et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians 71(3), 209-249. DOI : 10.3322/caac.21660
  2. M. E. McLaughlin-Drubin & K. Munger. (2008). Viruses associated with human cancer. Biochimica et Biophysica Acta 1782(3), 127-150. DOI : 10.1016/j.bbadis.2007.12.005
  3. J. M. M. Walboomers et al. (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. The Journal of Pathology 189(1), 12-19. DOI : 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F
  4. B. G. Kim. (2015). Update of human papillomavirus vaccination. Journal of the Korean Medical Association 58(4), 313-318. DOI : 10.5124/jkma.2015.58.4.313
  5. A. Asiaf et al. (2014). Review of the current knowledge on the epidemiology, pathogenesis, and prevention of human papillomavirus infection. European Journal of Cancer Prevention 23(3), 206-224. DOI : 10.1097/CEJ.0b013e328364f273
  6. R. Reid et al. (1982). Genital warts and cervical cancer. I. Evidence of an association between subclinical papillomavirus infection and cervical malignancy. Cancer 50(2), 377-387. DOI : 10.1002/1097-0142(19820715)50:2<377::AID-CNCR2820500236>3.0.CO;2-A
  7. Future II Study Group. (2007). Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New England Journal of Medicine 356(19), 1915-1927. DOI : 10.1056/NEJMoa061741
  8. World Health Organization. (2017). Human papillomavirus vaccines: WHO position paper, May 2017 Wkly Epidemiol Rec. 2217;92(19), 241-68.
  9. K. N. Lee et al. (2017). Attitudes regarding HPV vaccinations of children among mothers with adolescent daughters in Korea. Journal of Korean Medical Science 32(1), 130-134. DOI : 10.3346/jkms.2017.32.1.130
  10. A. M. Park & S. B. Koh. (2008). Prevalence and Distribution of Single and Multiple HPV Infections in Cervical Cancer and Precancerous Lesion From Daegu and Gyeongbuk Province. Korean Journal of Obstetrics and Gynecology 51(10), 1128-1136.
  11. AT. Lorincz et al. (1987). Oncogenic association of specific human papillomavirus types with cervical neoplasia. Journal of the National Cancer Institute 79(4), 671-677. DOI : 10.1093/jnci/79.4.671
  12. R. Sankaranarayanan et al. (2009). HPV screening for cervical cancer in rural India. New England Journal of Medicine, 360(14), 1385-1394. DOI : 10.1056/NEJMoa0808516
  13. H. R. Shin et al. (2003). Prevalence of human papillomavirus infection in women in Busan, South Korea. International Journal of Cancer 103(3), 413-421. DOI : 10.1002/ijc.10825
  14. W. D. Joo et al. (2004). Prevalence of human papillomavirus infection in Korean women: risks of abnormal pap smear and cervical neoplasia. Korean Journal of Gynecologic Oncology and Colposcopy 15.4, 309-316. DOI : 10.3802/kjgoc.2004.15.4.309
  15. S. K. Kjaer et al. (2010). Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Journal of the National Cancer Institute 102.19, 1478-1488. DOI : 10.1093/jnci/djq356
  16. K. K. Vesco et al. (2011). Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the US Preventive Services Task Force. Annals of Internal Medicine 155(10), 698-705, W216. DOI : 10.7326/0003-4819-155-10-201111150-00377
  17. G Ronco et al. (2014). Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. The Lancet 383(9916), 524-532. DOI : 10.1016/S0140-6736(13)62218-7
  18. H. R. Shin et al. (2004). Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. Journal of Infectious Diseases 190(3), 468-476. DOI : 10.1086/421279
  19. E. Lazcano-Ponce et al. (2001). Epidemiology of HPV infection among Mexican women with normal cervical cytology. International Journal of Cancer 91(3), 412-420. DOI : 10.1002/1097-0215(20010201)91:3<412::AID-IJC1071>3.0.CO;2-M
  20. R. Herrero et al. (2000). Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. Journal of the National Cancer Institute 92(6), 464-474. DOI : 10.1093/jnci/92.6.464
  21. K. A. et al. (2016). The impact of high-risk HPV genotypes other than HPV 16/18 on the natural course of abnormal cervical cytology: a Korean HPV cohort study. Cancer Research and Treatment 48(4), 1313-1320. DOI : 10.4143/crt.2016.013
  22. S. H. Kim et al. (2009). Factors related to human papilloma virus infection rate in women. Korean Journal of Family Medicine 30(12), 972-978. DOI : 10.4082/kjfm.2009.30.12.972
  23. N. Munoz et al. (2006). Chapter 1: HPV in the etiology of human cancer. Vaccine 24 (Suppl 3), S1-S10. DOI : 10.1016/j.vaccine.2006.05.115
  24. S. J. Goldie et al. (2007). Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25(33), 6257-6270. DOI : 10.1016/j.vaccine.2007.05.058